A Strong Partner in Europe
With over 600 clients globally and 40+ engagements in Europe, EVERSANA™ is leading the way as the only end-to-end provider of commercialisation services that span all stages of the product life cycle to deliver long-term value for patients, physicians and payers.
The UK, EU4 and emerging markets across eastern Europe present a major opportunity for biotechnology companies. However, many such companies decide to license their products to partner companies, assuming that launching across markets in Europe is complex. The result: Often, the product fails to achieve its full value. To be globally competitive, EVERSANA can work with you to assess and adapt your development and commercialization strategies to retain the value of your product.
A Global End-to-End Commercialisation Partner
Today’s global pharmaceutical industry is evolving into uncharted territories. Opportunities in drug pricing, access, reimbursement, adherence and product delivery shift every day, and you need agile solutions to keep up with new market challenges. With many European biotech launching their first product in the U.S. EVERSANA offers custom solutions for your product, patients and other key stakeholders. Now you don’t have to face the unknowns of commercialisation alone. EVERSANA infrastructure and partnership mentality, makes commercialisation in the U.S. predictable and our innovative models make success predictable.
Explore These Solutions
- U.S. Commercialisation
- Commercial Readiness for Europe
- Medical Information Call Centres
- Launch Strategy and Launch Sequence Optimization
- Patient Finder & Engagement
Schedule a Meeting
Talk with our business experts to learn more about how our global commercial solutions provide you with the right strategies and tools to help accelerate your speed to market. Click the button below to schedule a meeting.
To learn more about our global solutions visit: https://www.eversana.com/global/europe/.